Representative Greg Stanton (Democratic-Arizona) recently sold shares of Trulieve Cannabis Corp. (OTCMKTS:TCNNF). In a filing disclosed on June 26th, the Representative disclosed that they had sold between $100,001 and $250,000 in Trulieve Cannabis stock on May 28th.
Representative Greg Stanton also recently made the following trade(s):
- Sold $15,001 – $50,000 in shares of Trulieve Cannabis (OTCMKTS:TCNNF) on 5/6/2026.
Trulieve Cannabis Price Performance
TCNNF stock opened at $11.55 on Tuesday. Trulieve Cannabis Corp. has a 12 month low of $3.25 and a 12 month high of $13.28. The firm has a 50-day moving average price of $9.58 and a 200-day moving average price of $8.01.
Wall Street Analysts Forecast Growth
View Our Latest Research Report on Trulieve Cannabis
About Representative Stanton
Greg Stanton (Democratic Party) is a member of the U.S. House, representing Arizona’s 4th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027.
Stanton (Democratic Party) is running for re-election to the U.S. House to represent Arizona’s 4th Congressional District. He declared candidacy for the 2026 election.
Greg Stanton was born in Long Island, New York. Stanton graduated from Cortez High School. He earned a B.A. in political science and history from Marquette University in 1992 and a J.D. from the University of Michigan in 1995. Stanton’s career experience includes working as the mayor of Phoenix, deputy attorney general of Arizona, as an education attorney, and on the Phoenix City Council.
Trulieve Cannabis Company Profile
Trulieve Cannabis Corp. is a vertically integrated cannabis operator and retailer, offering a full suite of services from cultivation and processing to distribution and sales. The company develops, manufactures and markets a diverse range of cannabis products under its own brand portfolio, serving both medical and adult-use consumers through a network of branded dispensaries and delivery services.
Trulieve’s product lineup includes dried flower, vape cartridges, concentrates, edibles, tinctures and topicals, all of which are produced in compliance with state regulatory requirements.
See Also
- Five stocks we like better than Trulieve Cannabis
- The AI Boom Has a Second Act—And It’s Playing Out in Optics
- Gold’s 2026 Rally Has Cracked—Is It Time to Buy the Pullback?
- 5 Tech Stocks to Buy on the July Pullback
- Is OpenAI’s IPO Delay a Warning for AI Investors?
Receive News & Ratings for Trulieve Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trulieve Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.
